Accelerated Approval from FDA for Sunvozertinib in Metastatic NSCLC Featuring EGFR Exon 20 Insertion Mutations

Accelerated Approval from FDA for Sunvozertinib in Metastatic NSCLC Featuring EGFR Exon 20 Insertion Mutations

Accelerated Approval from FDA for Sunvozertinib in Metastatic NSCLC Featuring EGFR Exon 20 Insertion Mutations